Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.85
Bid: 2.70
Ask: 3.00
Change: 0.30 (11.76%)
Spread: 0.30 (11.111%)
Open: 2.55
High: 2.85
Low: 2.55
Prev. Close: 2.55
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx gets US patent protection for use of VAL201 peptide

Wed, 26th Jun 2019 10:53

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.The AIM-traded firm explained that advanced prostate cancer was classified when disease spread beyond the prostate to other parts of the body.That spread was known as metastatic disease, and in prostate cancer the most common spread was to the bones and lymph nodes.The company said the main goals for treatment of advanced prostate cancer were symptom control, slowing the rate at which the cancer grows, as well as targeting the tumour.ValiRx claimed the VAL201 compound "selectively prevents" tumour growth, by specifically inhibiting the proliferation of tumour cells.It said its inhibitory effects on lymph node metastases had been demonstrated in the pre-clinical prostate cancer model.The compound was currently in a phase 1 and 2 study, primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.VAL201 had been well tolerated, the firm claimed, with signs of activity in advanced prostate cancer noted through biomarker and imaging techniques."With previously granted worldwide rights for the use of VAL201 in prostate cancer, we are very pleased that the USPTO has allowed claims for the use of VAL201 in the prevention and treatment of metastatic - including prostate - cancer," said ValiRx chief executive officer Dr Satu Vainikka."I believe that not only will the allowed claims complement our other intellectual property and provide the company with a more compelling package to offer when in discussions with big pharma, but I also believe that if we can reduce the symptoms and progression of metastases, as well as targeting the lesion, through the use of VAL201, we can improve prospects for patients."
More News
2 Feb 2012 12:17

Small caps round-up: Caza, Tower Resources, Noventa...

Mining firm Noventa says that operations have suffered from a "plague" of beetles as a result of tropical storms which have hit the firm's Marropino site in Mozambique over the past 10 days. The Rove Beetle is very poisonous and around 30% of the workforce at Marropino have been affected by the seve

Read more
15 Dec 2011 09:21

Valirx wins Canadian patent for 'gene-silencing' technology

ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada. It already has patents for the US, Europe and Australia. ValiRx is developing treatments which "silence" so called rebellious genes that can cau

Read more
15 Jul 2010 07:40

ValiRx Begins Clinical Validation Of HPV Test

LONDON (Dow Jones)--ValiRx PLC (VAL.LN), a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, said Thursday its human papilloma virus, or HPV, smear test to detect the onset of cervical cancer in women has now begun clinical sample validation. MAI

Read more
17 Jun 2010 08:14

Small caps round-up: Nyota Minerals, Mariana Resources, Bluestar...

Miner Nyota Minerals said drilling at its flagship Tulu Kapi gold project in Ethiopia has confirmed the presence of a new mineralized structure beneath the inferred resource of 1.38m ounces of gold. Also in gold mining, Mariana Resources said it made an encouraging intersection of gold north of the

Read more
17 Jun 2010 07:36

ValiRx Completes 1st Yr Eurostars Program, All Milestones Met

LONDON (Dow Jones)--ValiRx Plc (VAL.LN), a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, announced Thursday that it has completed the first year of a two year Eurostars grant program (total budget EUR1.2 million) in which all developmental milest

Read more
24 May 2010 13:42

London afternoon: Back to square one

Footsie has limped back into positive territory, helped by an about turn by the mining stocks. After spending the morning down in the dumps Rio Tinto is now the best performing mining stock as metal prices head northwards. Fellow mining stocks Xstrata and Anglo American join Rio on the rise but S

Read more
24 May 2010 07:52

Small caps: Cineworld, Aortech, African Eagle

Cinema chain Cineworld has signed a deal with Quintain Estates for a new multi-screen cinema at Wembley City, the retail park next door to Wembley station. Cineworld has signed a 25 year lease for a new nine screen cinema which will seat 1,800 people in total and is scheduled to open in 2013. It w

Read more
9 Mar 2010 14:31

Small caps round-up: Chaarat Gold, Leed Petroleum, Zotefoams...

Gold explorer Chaarat continues its year-long rally after increasing resources at its 100%-owned Chaarat deposit in the Kyrgyz Republic from 3.3m to 4m ounces. "This continues to demonstrate the significant potential of the deposit which will allow the company to pursue a low cost gold mining opera

Read more
14 Sep 2009 14:00

Sector movers: Chemical sector reacts to Johnson Matthey downgrade

Johnson Matthey is helping drag the chemicals sector lower. The platinum refiner and catalytic converter maker was downgraded to 'equal-weight' from 'overweight' at Morgan Stanley. Elsewhere in chemicals, Plant Health Care falls back slightly after depressed agricultural markets resulted in widenin

Read more
14 Sep 2009 09:51

Small caps round-up: IS Solutions, Netservices, Plant Health Care...

Higher revenues helped software services group IS Solutions post broadly unchanged profits in the six months to June 30. Pre-tax profits for the period totalled £184,000, compared with £189,000 the previous year, as revenues soared to £5.12m from £3.64m. During the year, the company completed the p

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.